BAUSCH+ Health

Bausch Health Companies Inc. completes name change

July 13, 2018

Bausch Health Will Begin Trading as "BHC" on NYSE and TSX on Monday, July 16

LAVAL, Quebec, July 13, 2018 – Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health" or the "Company" or "we") today announced the Company's name change from Valeant Pharmaceuticals International, Inc. to Bausch Health Companies Inc. is complete.

"Choosing Bausch Health as our new corporate name is very meaningful, because the Bausch name has long been a highly respected name in the health care space, synonymous for 165 years with innovation and an unwavering dedication to improving people's lives," said Joseph C. Papa, chairman and CEO, Bausch Health. "It is a legacy that defines us today and sets the stage for our future as we continue to transform the Company."

Bausch Health will begin trading as "BHC" on the New York Stock Exchange and Toronto Stock Exchange on July 16, 2018.

As part of the name change, Bausch Health has unveiled a new corporate brand visual identity, and on July 16, 2018, will launch a new corporate web site: www.bauschhealth.com
.

Because the Company's businesses and subsidiaries have strong brand equity, all entities that have separate established brands will continue to operate under the corporate umbrella using their existing names.

About Bausch Health

Bausch Health Companies Inc. (NYSE/TSX: BHC) is a global company whose mission is to improve people's lives with our health care products. We develop, manufacture and market a range of pharmaceutical, medical device and over-the-counter products, primarily in the therapeutic areas of eye health, gastroenterology and dermatology. We are delivering on our commitments as we build an innovative company dedicated to advancing global health.

Forward-looking Statements

This news release may contain forward-looking statements, which may generally be identified by the use of the words "anticipates," "expects," "intends," "plans," "should," "could," "would," "may," "will," "believes," "estimates," "potential," "target," or "continue" and variations or similar expressions. These statements are based upon the current expectations and beliefs of

Eye Therapies Exhibit 2178, 1 of 2
Dr. Reddy's v. Eye Therapies - IPR2024-00467

management and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. These risks and uncertainties include, but are not limited to, risks and uncertainties discussed in the Company's most recent annual or quarterly report and detailed from time to time in the Company's other filings with the Securities and Exchange Commission and the Canadian Securities Administrators, which factors are incorporated herein by reference. In addition, certain material factors and assumptions have been applied in making these forward-looking statements, including that the risks and uncertainties outlined above will not cause actual results or events to differ materially from those described in these forward-looking statements. The Company believes that the material factors and assumptions reflected in these forward-looking statements are reasonable, but readers are cautioned not to place undue reliance on any of these forward-looking statements. These forward-looking statements speak only as of the date hereof. Bausch Health undertakes no obligation to update any of these forward-looking statements to reflect events or circumstances after the date of this news release or to reflect actual outcomes, unless required by law.

###

IR and Communications Contacts

General Investor Relations
Email: ir@bauschhealth.com
877-281-6642
514-856-3855 (Canada)

Media inquiries

Kevin Wiggins
Email:
Corporate.communications@bauschhealth.com
Office: 908-927-1722

LEGAL NOTICE PRIVACY POLICY

EMAIL ALERTS EMAIL PAGE RSS FEED

Use of this site signifies your agreement to the Legal Notice and Privacy Policy.
©2021 Bausch Health Companies Inc. All rights reserved. MTB.0230.USA.18 V2.0

CALIFORNIA RESIDENTS: DO NOT SELL MY PERSONAL INFORMATION

Powered by SITECORE

Eye Therapies Exhibit 2178, 2 of 2
Dr. Reddy's v. Eye Therapies - IPR2024-00467